| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2027 ( Subtotal = -$82,213 ) |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P01CA250984 | Identifying Metabolic Vulnerabilities in Lung Cancer | 000 | 5 | NIH | 10/28/2026 | $0 |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA253219 | Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults | 000 | 6 | NIH | 11/2/2026 | $0 |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 000 | 5 | NIH | 11/2/2026 | -$35,766 |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 000 | 2 | NIH | 10/29/2026 | $0 |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 000 | 2 | NIH | 10/13/2026 | $0 |
| | 2027 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279023 | Epigenetic and metabolic bottlenecks of tumorigenesis | 000 | 2 | NIH | 11/2/2026 | $0 |
| | 2027 | 2024 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA242742 | Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors | 000 | 5 | NIH | 10/30/2026 | -$46,446 |
|
| Issue Date FY: 2026 ( Subtotal = $48,210,855 ) (Continued on the next page) |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01DE033329 | Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | 001 | 4 | NIH | 7/22/2026 | $707,563 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 4 | NIH | 4/20/2026 | $65,716 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 4 | NIH | 2/10/2026 | $591,443 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA276939 | Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma | 000 | 3 | NIH | 6/19/2026 | $669,302 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U24CA284167 | Developing a Cancer Galaxy Computational Workbench to Meet Emerging Cancer Data Analysis Needs | 002 | 3 | NIH | 9/4/2026 | $1,026,346 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U24CA284167 | Developing a Cancer Galaxy Computational Workbench to Meet Emerging Cancer Data Analysis Needs | 002 | 3 | NIH | 9/4/2026 | $199,999 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA261598 | Ending Tobacco Use through Interactive Tailored Messaging for Cambodian People Living with HIV/AIDS (EndIT) | 002 | 6 | NIH | 9/4/2026 | $154,356 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA261598 | Ending Tobacco Use through Interactive Tailored Messaging for Cambodian People Living with HIV/AIDS (EndIT) | 001 | 6 | NIH | 8/26/2026 | $398,198 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01CA200464 | Quantitative Imaging Clinical Validation Center at Moffitt Cancer Center | 001 | 9 | NIH | 8/11/2026 | $1,322,710 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA266727 | Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy | 000 | 5 | NIH | 9/7/2026 | $520,099 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA264518 | Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy | 000 | 5 | NIH | 8/26/2026 | $668,909 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA281756 | Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy | 001 | 3 | NIH | 7/15/2026 | $2,068,249 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA291735 | A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers | 001 | 3 | NIH | 8/27/2026 | $2,037,289 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P30CA076292 | Moffitt Cancer Center Support Grant | 000 | 28 | NIH | 5/26/2026 | $4,054,822 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 001 | 3 | NIH | 3/5/2026 | $62,113 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 3 | NIH | 12/11/2025 | $559,022 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U54CA274507 | The Delta Ecology of NSCLC Treatment | 001 | 4 | NIH | 9/17/2026 | $1,538,725 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA287666 | Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | 001 | 3 | NIH | 8/28/2026 | $1,988,242 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 001 | 3 | NIH | 7/8/2026 | $1,448,091 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA310579 | Targeting mitochondrial stress responses in melanoma to enhance immunotherapy | 000 | 1 | NIH | 5/1/2026 | $40,393 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | F31CA310579 | Targeting mitochondrial stress responses in melanoma to enhance immunotherapy | 001 | 1 | NIH | 5/1/2026 | $0 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 001 | 3 | NIH | 6/26/2026 | $1,659,122 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 3 | NIH | 1/16/2026 | $610,534 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 3 | NIH | 4/16/2026 | $67,835 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99GM154063 | Dual E3 ligase function of TRIM25 in modulating innate immunity | 001 | 2 | NIH | 3/10/2026 | $113,234 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 002 | 5 | NIH | 9/15/2026 | $179,115 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 001 | 5 | NIH | 9/14/2026 | $109,004 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA274950 | Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | 000 | 5 | NIH | 9/3/2026 | $319,556 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 5 | NIH | 6/30/2026 | $481,119 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255398 | Characterizing oncogenic function of ITCH in melanoma | 000 | 6 | NIH | 6/26/2026 | $357,913 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA309659 | Cysteine Acquisition and Utilization in Lung Adenocarcinoma | 000 | 1 | NIH | 5/13/2026 | $687,593 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21AG100933 | Deciphering the contribution of the aged alveolar niche to lung cancer evolution | 000 | 1 | NIH | 6/11/2026 | $463,375 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA244328 | Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | 000 | 5 | NIH | 7/8/2026 | $1,044,728 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 6 | NIH | 2/27/2026 | $444,589 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | T32CA233399 | Integrated Program in Cancer and Data Science (ICADS) | 001 | 6 | NIH | 7/6/2026 | $122,540 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299480 | The MIND-BC Study: MIND diet for Breast cancer Cognition | 000 | 2 | NIH | 3/19/2026 | $696,013 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R50CA211447 | Developing chemical probes for oncogenic signaling pathways | 000 | 9 | NIH | 8/19/2026 | $293,933 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R34CA297368 | Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers | 000 | 2 | NIH | 5/14/2026 | $312,790 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE034377 | Ultrasensitive detection of circulating DNA methylation for head and neck cancer prognosis | 000 | 2 | NIH | 6/11/2026 | $712,674 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering supplement | 001 | 7 | NIH | 3/10/2026 | $46,337 |
| | 2026 | 2026 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering supplement | 002 | 7 | NIH | 9/9/2026 | $89,222 |
|
